Latest news
Merck advances sac-TMT into first-line lung cancer redesign after endometrial Phase III win - AllSciAllSci · Wed, 05 Aug 2026 09:44:57 GMTKaryopharm’s selinexor misses primary endpoint in Phase 3 endometrial cancer trial - The Clinical Trial VanguardThe Clinical Trial Vanguard · Sat, 01 Aug 2026 06:33:05 GMTSelinexor Maintenance Misses Mark in TP53 Wild-Type Endometrial Cancer - Targeted OncologyTargeted Oncology · Fri, 31 Jul 2026 20:06:29 GMTSelinexor Maintenance Misses PFS End Point in TP53 Wild-Type Endometrial Cancer - OncLiveOncLive · Fri, 31 Jul 2026 17:22:55 GMTSelinexor Misses PFS End Point in TP53 Wild-Type Endometrial Cancer - CancerNetworkCancerNetwork · Fri, 31 Jul 2026 14:37:53 GMTXpovio mulligan in endometrial cancer comes up short as Karyopharm presses on in myelofibrosis - fiercepharma.comfiercepharma.com · Fri, 31 Jul 2026 14:00:00 GMTSelinexor Phase 3 Trial Misses Primary Endpoint in Endometrial Cancer - The Clinical Trial VanguardThe Clinical Trial Vanguard · Fri, 31 Jul 2026 07:37:59 GMTKaryopharm slumps after Xpovio misses mark in Phase III endometrial cancer study - FirstWord PharmaFirstWord Pharma · Thu, 30 Jul 2026 21:59:38 GMT